Northwest & Ethical Investments L.P. trimmed its stake in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX – Free Report) by 34.0% in the 3rd quarter, HoldingsChannel reports. The firm owned 9,902 shares of the company’s stock after selling 5,100 shares during the quarter. Northwest & Ethical Investments L.P.’s holdings in GoodRx were worth $69,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also modified their holdings of the stock. nVerses Capital LLC purchased a new stake in GoodRx during the third quarter valued at about $33,000. Plato Investment Management Ltd acquired a new stake in shares of GoodRx during the second quarter valued at approximately $43,000. Dark Forest Capital Management LP acquired a new position in GoodRx in the 2nd quarter worth approximately $86,000. Quest Partners LLC acquired a new position in GoodRx in the 3rd quarter worth approximately $160,000. Finally, Deerfield Management Company L.P. Series C purchased a new position in GoodRx during the 2nd quarter worth approximately $173,000. Institutional investors and hedge funds own 63.77% of the company’s stock.
Insider Buying and Selling at GoodRx
In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the business’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.86, for a total transaction of $83,921.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 4.17% of the company’s stock.
GoodRx Stock Performance
Wall Street Analysts Forecast Growth
Several brokerages have recently commented on GDRX. Citigroup decreased their target price on GoodRx from $10.00 to $7.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. UBS Group lowered their target price on GoodRx from $9.00 to $8.50 and set a “neutral” rating on the stock in a research note on Friday, August 9th. Barclays reduced their price target on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a research report on Monday, November 11th. Raymond James raised shares of GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price objective on the stock in a research report on Friday, August 9th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 target price on shares of GoodRx in a research report on Friday, August 16th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $8.86.
Get Our Latest Stock Analysis on GDRX
GoodRx Profile
GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.
Recommended Stories
- Five stocks we like better than GoodRx
- The 3 Best Fintech Stocks to Buy Now
- Analog Devices: Why the Uptrend Could Accelerate in 2025
- What is the S&P 500 and How It is Distinct from Other Indexes
- Texas Pacific Land: Permian Basin Powerhouse With an AI Edge
- What is the S&P/TSX Index?
- ServiceNow: Will the High-Flyer Finally Split in 2024?
Want to see what other hedge funds are holding GDRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GoodRx Holdings, Inc. (NASDAQ:GDRX – Free Report).
Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.